Cambrex Corp. has successfully completed an FDA inspection of its API manufacturing facility in Charles City, IA. The inspection found the site to be compliant with GMP principles and guidelines, with no Form 483 observations issued. The FDA inspected the facility from July 31 to August 2, 2013.
Joe Nettleton, Cambrex’ vice president operations and Charles City site director, said, "We are very pleased with the results of this latest FDA inspection, which further strengthens our track record of outstanding regulatory compliance. We commit significant resources and work diligently to maintain high quality standards and continuously improve quality platforms within Cambrex.”